Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC

Launched by FUDAN UNIVERSITY · Apr 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a specific type of lung cancer known as non-small cell lung cancer (NSCLC), particularly focusing on patients who have changes in certain genes (RB1 and TP53) that may increase the risk of the cancer transforming into a different, more aggressive type called neuroendocrine carcinoma (NEC). This transformation can happen in some patients who are resistant to standard treatments. The researchers want to learn more about how often this change occurs and how it affects treatment options. They will follow these patients closely, collecting information about their health and conducting repeat biopsies, which involve taking small samples of tissue to examine for changes in the cancer.

To be eligible for this trial, participants need to be at least 18 years old and diagnosed with advanced stage NSCLC that has not yet transformed into neuroendocrine carcinoma. They should also have confirmed dual inactivation of the RB1 and TP53 genes through testing. Patients must have undergone at least one treatment for their cancer and agree to provide blood and tissue samples during the study. Throughout the trial, participants will be carefully monitored, and those who experience disease progression will undergo additional testing to help researchers understand the disease better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old;
• • 2. ECOG function status score 0-2 points;
• • 3. Pathological diagnosis of stage III-IV non neuroendocrine non-small cell lung cancer;
• • 4. RB1/TP53 gene/protein testing (IHC, NGS, or other techniques are acceptable) has been completed and confirmed to be dual inactivation of RB1/TP53;
• • 5. For patients with baseline pathology of adenocarcinoma, complete driver gene testing (including at least EGFR and ALK);
• • 6. The patient undergoes at least one systemic treatment (chemotherapy, targeted drug therapy, immunotherapy, etc.) and receives regular follow-up;
• • 7. After discovering disease progression during the follow-up process, the patient will undergo further pathological biopsy of the progressing lesion after evaluation by the sub center PI;
• • 8. According to the researcher's assessment, the patient currently does not require palliative radiation therapy in any area;
• • 9. If the subject undergoes surgery, they must fully recover from the toxicity and complications of the surgical intervention before starting treatment;
• • 10. The subjects need to agree to provide corresponding peripheral blood and biopsy tissue samples before and during the follow-up treatment in accordance with the clinical trial protocol requirements;
• • 11. Men/women of childbearing age agree to use contraception during the trial period (surgical ligation or oral contraception/intrauterine device+condom contraception);
• • 12. Life expectancy ≥ 3 months;
• • 13. Patients must have the ability to understand and voluntarily sign informed consent forms.
• Exclusion Criteria:
• • 1. Baseline pathological examination reveals neuroendocrine components (including any percentage of small cell carcinoma, large cell carcinoma, differentiated neuroendocrine carcinoma, etc);
• • 2. Unable to perform RB1/TP53 testing ;
• • 3. Patients with baseline pathology of adenocarcinoma and inability to perform driver gene testing (including at least EGFR, ALK);
• • 4. Symptomatic interstitial lung disease or active infection/non infectious pneumonia;
• • 5. History of other malignant tumors;
• • 6. Physical examination or clinical trial findings that researchers believe may interfere with the results or increase the risk of treatment complications for patients, or other uncontrollable diseases
• • 7. Breastfeeding or pregnant women;
• • 8. Congenital or acquired immunodeficiency diseases, including human immunodeficiency virus (HIV), or a history of organ transplantation or allogeneic stem cell transplantation;
• • 9. Patients who require long-term treatment with cortisol or immunosuppressants;
• • 10. Patients with mental illnesses, substance abuse, or social issues that affect compliance will not be included in the group after being reviewed by a doctor
• • 11. Individuals who receive other long-term medication treatments and have been assessed by a doctor as potentially affecting disease progression.